Coloplast A/s Class B · OMXCOP:COLO_B
Coloplast A/s Class B — Non-Deal Roadshow (August 2023)
108 slides from Coloplast A/s Class B's roadshow presentation, August 2023
Slide 1: Roadshow presentation 9M 2022/23
Roadshow presentation 9M 2022/23 Morten, Denmark Making life easier STRIVE25: SUSTAINABLE GROWTH LEADERSHIP
Slide 2: Forward-looking statements
Forward-looking statements The forward-looking statements contained in this presentation, including forecasts of sales and earnings performance, are not guarantees of future results and are subject to risks, uncertainties and assumptions that are difficult to predict. The forward-looking statements
Slide 3: Solid Q3 with 8% organic growth and 28% EBIT margin
Solid Q3 with 8% organic growth and 28% EBIT margin1. FY 2022/23 guidance unchanged at ~8% organic growth and 28-29% EBIT margin1 REVENUE GROWTH Q3 2022/23 highlights • Organic growth of 8% (reported growth in DKK 4%). Organic growth by business area: Ostomy Care 8%, Continence Reported revenue (mDK
Slide 4: With Kerecis, Coloplast adds a long-term growth business
With Kerecis, Coloplast adds a long-term growth business, uniquely positioned to support Coloplast’s long-term value creation Kerecis - financial assumptions Our updated long-term financial guidance will drive continued long-term value creation • FY 2022/23 revenue growth of around 50% • Three-year
Slide 5: Q3 growth of 8% was broad-based across business areas and regions
Q3 growth of 8% was broad-based with contribution from all business areas and regions Q3 2022/23 revenue by business area Q3 2022/23 revenue by geography Business Reported revenue Organic growth Share of organic Geographic Reported revenue Organic growth Share of organic area DKKm growth area DKKm g
Slide 6: Solid Q3 in Ostomy Care with broad-based growth of 8%
Solid Q3 in Ostomy Care with broad-based growth of 8%. China grew double-digit due to a lower baseline and normalized hospital activity Ostomy Care performance Q3 2022/23 highlights • All regions contributed to growth in the quarter 13 • Strong quarter in Emerging markets, led by China • China poste
Slide 7: Strong Q3 in Continence Care with 9% growth
Strong Q3 in Continence Care with 9% growth. Solid contribution across product groups, incl. Collecting Devices, following backorder resolution Continence Care performance Q3 2022/23 highlights • Solid contribution to growth from all regions • Continued good sales momentum in the US and Europe, led
Slide 8: Continued solid momentum in Voice & Respiratory Care
Continued solid momentum in Voice & Respiratory Care with 9% organic growth in Q3, driven by both Laryngectomy and Tracheostomy Voice & Respiratory Care performance Q3 2022/23 highlights • Voice and Respiratory Care delivered 9% organic growth • Laryngectomy delivered high single-digit organic growt
Slide 9: Wound Care grew 5% in Q3, driven by China
Wound Care grew 5% in Q3, driven by double-digit growth in China, while growth in Europe was held back by backorders Wound & Skin Care performance Q3 2022/23 highlights • Wound and Skin Care grew 4%, while Wound Care in isolation grew 5% 14 10 13 • China delivered double-digit growth in Q3 and benef
Slide 10: 7% Q3 growth in Interventional Urology
7% Q3 growth in Interventional Urology, from a high baseline last year. Continued broad-based growth across geographies and business areas Interventional Urology performance Q3 2022/23 highlights • Growth in the quarter was driven by continued strong momentum across business areas and geographies, a
Slide 11: Reported revenue grew 4% in Q3
Reported revenue grew 4% in Q3, reflecting solid organic growth of 8% and significant headwind from exchange rates development Q3 2022/23 Revenue development (DKKm) Q3 2022/23 highlights • Organic growth was 8% or DKK 450 million, driven by: +259m DKK • Continued solid momentum in Chronic Care acros
Slide 12: Reported EBIT margin of 28% in Q3
Reported EBIT margin of 28%1 in Q3, reflecting mostly inflationary headwind on input costs. Significant negative currency impact in Q3 Q3 2022/23 EBIT margin development before special items (%) Q3 2022/23 highlights • Gross margin was 66%, against 69% in Q3 last year • Negative impact from: raw mat
Slide 13: Adj. FCF in 9M was DKK 2,167 million
Adj. FCF in 9M was DKK 2,167 million. Operating cash flow impacted by increased working capital; NWC-to-sales now expected at 25% for FY FCF development1 FCF development Comments 9M 2022/23 highlights • Free cash flow for 9M 2022/23 was an inflow of DKK 1,690 million compared to an outflow of DKK 8,
Slide 14: FY 2022/23 guidance – organic growth around 8%
FY 2022/23 guidance – organic growth of around 8% and reported EBIT margin of 28-29%1 GUIDANCE 2022/23 GUIDANCE (DKK)* KEY ASSUMPTIONS • Chronic Care ex. China expected to grow largely in line with Strive25 ambitions: Europe – continued good momentum; US – sustained good momentum in Ostomy Care and
Slide 15: FY 2022/23 guidance breakdown: input cost impact on EBIT margin
FY 2022/23 guidance breakdown: significant negative impact from input cost increases on EBIT margin Development since issue of FY guidance in November 2022 Revenue growth assumptions Key impacts on gross- and EBIT margin development in 2022/23 Positive Unchanged Negative FY 2022/23 organic growth ex
Slide 16: Making it easier to be yourself
Making it easier to be yourself Leading intimate healthcare Introduction to Coloplast Stina | OC user
Slide 17: Coloplast has five business areas with global sales presence
Coloplast has five business areas all with global sales presence Group revenue 2021/22 by segment1 Group revenue 2021/22 by geography 1 Continence Care 34% European 1 markets 57% Ostomy Care Other developed 38% markets DKK DKK 26% 22.6bn 22.6bn 1 Voice & Respiratory 4 Care Interventional 5% Urology
Slide 18: Coloplast specializes in intimate healthcare needs
Coloplast specializes in intimate healthcare needs Who are our typical users How do we help them? Ostomy Care People who have had their intestine redirected to SenSura® Mio an opening in the abdominal wall Ostomy bag Continence Care People in need of bladder or bowel management SpeediCath® Flex Flex
Slide 19: The Chronic Care model secures a predictable revenue stream
The Chronic Care model secures a predictable revenue stream and stable revenue growth The chronic care user flow Chronic Care condition New user Installed base of users Stable flow of loyal users Solid reimbursement Coloplast group revenues Revenue (DKK bn) Organic growth (%) 10 10 9 8 8 8 8 6 7 7 7
Slide 20: Intimate healthcare is characterized by stable industry trends
Intimate healthcare is characterized by stable industry trends 01. 01. Demographics Surgical and medical trends Growing elderly population Earlier detection and cure, increases customer base for eventually reduces addressable Coloplast products market for Coloplast treatment Limiters Drivers product
Slide 21: Strong market positions in Europe and potential outside Europe
Coloplast has strong market positions in Europe and great commercial potential outside Europe Europe Other developed Ostomy Continence Voice & Respiratory Interventional Wound Care Emerging Care Care Care (Laryngectomy) Urology (Adv. Dressings)* Addressable market 20-21bn 15-16bn 1–1.5bn 13-14bn 24-
Slide 22: We are building the consumer healthcare company of the future
We are building the consumer healthcare company of the future Macro Trends Impact Commercial model Ageing population Superior, clinically differentiated products Healthcare consumerism Digital transformation Consumer preference Data and Clinical digital tools preference Price pressure Channel consol
Slide 23: Our Strive25 strategy supports long-term value creation
Our Strive25 strategy supports continued long- term value creation through Continence Care revenue and earnings growth Ostomy Care Wound and Skin Care Long-term financial guidance Interventional Urology Voice and Respiratory Care Innovation Leadership, culture 8-10% more than 30% and organization or
Slide 24: Clear path to organic growth acceleration with Kerecis
Clear path to organic growth acceleration in the outer part of the Strive25 period and beyond with the addition of Kerecis +1%-point accretion 8-10% 7-9% ~8% Expected to Strive25 Strive25 Strive25 Organic growth become part of ambition: ambition: ambition: of 8-10% organic growth 10%+ organic Double
Slide 25: Strive25 emphasis on environmental performance
With Strive25 we put emphasis on improving our environmental performance, while continuing our ongoing commitments Our mission Making life easier for people with intimate healthcare needs Our 2025 priority Our 2025 priority Improving products Reducing emissions1 and Packaging1 90% of packaging recyc
Slide 26: Yearly incremental investments of up to 2% of revenue
We will continue to support organic growth through yearly incremental investments of up to 2% of revenue in the Strive25 period Key Investment Decision Drivers Key Investment Areas We expect to invest up to 2% Economics & Government Innovation of revenue in incremental OPEX investments Chronic Care
Slide 27: We will actively pursue M&A opportunities
We will actively pursue M&A opportunities as a lever for long-term growth Opportunity Systematic based screening Large plays Channel expansion Portfolio expansion Early-stage & adjacencies technologies Examples: Atos Medical Hope Medical Supply1 TFL Drive Nine Continents Kerecis (closing of the Rock
Slide 28: Key enablers supporting the commercial model in Chronic Care
We have built key enablers to support the commercial model in our Chronic Care businesses Commercial model Key enablers Superior, clinically Direct Businesses differentiated products Coloplast Consumer Care Consumer preference Data and digital tools Clinical preference Direct to Consumer Data & Digi
Slide 29: Direct business in Chronic Care drives growth
Direct business in Chronic Care serving consumers drives improved outcomes and is a vital component of our growth Direct presence in top 5 markets and strategic rationale Coloplast Consumer presence (incl. patient support programme, Coloplast® Care) Control and continuity 1 of product supply ~30% MS
Slide 30: Clinical Performance Programme to tackle biggest user issues
We have initiated a very ambitious Clinical Performance Programme to tackle the biggest issues users face 45 of users describe UTIs are their %* 2.7 UTIs per user on average every year1 93 % worry about leakage2 greatest challenge in life1 1 Source: Coloplast IC user survey, January 2016 (n=2,942),
Slide 31: Solid progress on Heylo and Luja
Solid progress on Heylo™ and Luja™; Luja is launched in five markets and is expected to be available in key markets over the next 6 months Status August 2023 Expected launch Product launch Luja™ • Product launched in five markets expected in key new catheter • Coloplast has presented the results of
Slide 32: Leakage remains the biggest challenge for our users
Leakage remains the biggest challenge for our users 91% of people with a stoma worry about leakage1 40 % of users experience leakage onto their clothes every month2 Heylo addresses the mental burden caused by fear of leakage Control and peace of mind 1. Claessenes et. al. Gastrointestinal Nursing 20
Slide 33: Data on Heylo is promising
Data on Heylo™ is promising. Pre-pilot study shows high product performance and user preference Product performance & user experience1 Quality of life and future use1 reduction in worry of leakage 92%* % +9 emotional impact of leakage significant improvement to less leakage episodes 85 %** % 96 secu
Slide 34: Clinical program supports launches and reimbursement applications
The clinical program supports national launches, reimbursement applications and generates user insights Single-arm confirmatory study, n=100 Show benefit to support Drug Tariff application: • Leakage onto clothes • Quality of Life • Healthcare utilisation • Support reimbursement in DE & UK Cross-ove
Slide 35: Preventing UTIs remains one of the biggest unmet needs
Preventing UTIs % remains one of the 45% 48 biggest unmet of users consider of users are UTIs to be their worried whether needs we need to greatest challenge1 they have emptied solve for in IC their bladder4 IC users have 2-3 UTIs on average per year…2 …over a lifetime users will have up to 1 IC Val
Slide 36: Luja catheter platform addresses key UTI risk factors
Luja™, our new catheter platform with Micro-hole Zone Technology™ addresses key UTI risk factors UTI Risk Factor Model1 UTI risk factors addressed by Luja™ Intermittent General patient catheterisation conditions UTI risk factor: UTI risk factor: Non-hygienic technique Urethral trauma UTI risk factor
Slide 37: Comprehensive clinical program behind Luja
Comprehensive clinical program behind Luja™ to demonstrate the clinical relevance and difference Pivotal studies 2 multinational pivotal studies2 involving 110+ users demonstrating the impact on the key risk factors of UTIs Pilot studies Multicenter, randomised cross 8 studies comparing Luja vs. ove
Slide 38: Profitability supported by scalability and efficiency gains
Profitability supported by scalability and efficiency gains enabling additional innovation and commercial investments Gross Profit development, %* Cost item Development, in % of revenue* YTD 22/23 Gross Profit negatively impacted by inflationary headwind on input +1.7%-points costs (raw materials, e
Slide 39: Automation, procurement and scale in Global Operations
Automation, procurement and scale are key to bringing Global Operations to the next level 1. Automation to mitigate growth in blue-collar FTE # of FTE release through automation, original plan • Due to longer component lead 9% ~600 >1,000 times, the timeline of the DKK ~450m ~500 CAPEX investment ov
Slide 40: Global Business Support and IT landscape
A global Business Support and IT landscape enables Coloplast to scale faster and efficiently and integrate Atos Medical into the Group Global Business Services Global business services handle the majority of all global support % of group processes 100% ~90% 100% 100% IT infrastructure Finance / acco
Slide 41: EBIT margin development drivers
EBIT margin development continues to be a function of growth, scalability, cost discipline and investment activity EBIT margin (%) Illustrative Future drivers of EBIT margin EBIT will be positively impacted by: Leverage effect on fixed costs e.g. distribution, admin and R&D costs >30% especially dri
Slide 42: Continued strong development in free cash flow
Continued strong development in free cash flow during the Strive25 strategy period Taxation Net working capital CAPEX2 Reported tax rate Net working capital, % of revenue CAPEX DKKm Depreciation and amortisation, % of revenue CAPEX, % of revenue 5% 5% 5% 6% 5% 4% 5% 4% 4% 4% 27% 4% 24% 23% 24% 25% ~
Slide 43: Attractive cash returns despite investments and acquisitions
We will continue to provide attractive cash returns despite investments in commercial activities and the Atos Medical and Kerecis acquisitions Coloplast cash distribution to investors Highlights Dividends paid out in the year (DKKm) (1) Share buy-back (DKKm) Pay-out ratio (%) (2) • Coloplast returns
Slide 44: Stable shareholder returns through growth and margin
In sum, we believe Coloplast can continue to deliver stable shareholder returns through ... Organic growth and EBIT margin development Highlights 28% • Stable market trends in our Chronic Care business • Innovative product portfolio and new product 12% launches 8% • Strong Coloplast Care retention p
Slide 45: Introduction to Kerecis
Introduction to Kerecis An emerging category leader in the biologics wound care segment
Slide 46: With Kerecis, Coloplast reaches more wound patients
With the addition of Kerecis, Coloplast aims to reach many more patients in need of wound treatment, accelerating growth to 8-10% Long-term financial guidance Mission: To become the world leader in tissue regeneration by sustainably harnessing nature’s own remedies 8-10% more than 30% organic growth
Slide 47: US-centric biologics segment is fastest growing in wound care
The US-centric biologics segment in which Kerecis operates is the fastest growing advanced wound care segment The advanced wound care market Size in DKKbn, growth in % The biologics wound care market ILLUSTRATIVE External Devices DKKbn growing low-single digit ~13 EU4+UK US High-single digit CAGR 20
Slide 48: Acquisition adds a long-term growth business
With the acquisition, Coloplast adds a long-term growth business and enters the attractive biologics segment Kerecis – a sustainable business with a clinically …well-positioned for long-term differentiated technology and a great fit to Coloplast… value creation Growth outlook: Shared mission of maki
Slide 49: Kerecis transforming wound healing with fish skin technology
Kerecis is transforming wound healing with its clinically differentiated technology platform based on gently processed fish skin Kerecis key business highlights Revenue distribution by Started in 2009, with headquarters and manufacturing in Iceland wound type DKK 510m Revenue for FY 2021/22 Propriet
Slide 50: Gently processed fish skin supports wound healing
The gently processed fish skin supports effective wound healing and has a sustainable and cost-efficient production setup Production and logistics: Product portfolio: Minimal and gentle processing of the fish skin Unique benefits of the technology platform • No known disease transmission from cold w
Slide 51: Transaction price up to USD 1.3 billion
Transaction price is up to USD 1.3 billion (around DKK 8.9 billion) with closing expected during Q4 2022/23 • Coloplast acquires Kerecis for an enterprise value of up to USD 1.3 billion (around DKK 8.9 billion) Structure and • Total price for 100% of the share capital is USD 1.2 billion (around DKK
Slide 52: Introduction to Atos Medical
Introduction to Atos Medical The global market leader in laryngectomy | Atos user
Slide 53: Atos Medical is the global pioneer within Laryngectomy
Atos Medical is the global pioneer within Laryngectomy and has shaped the market for the past +30 years Key market and business highlights Revenue by segment and geography Laryngectomy Tracheostomy Other ~50,000 New total laryngectomies per year Organic CAGR ~8% ~85% Global Laryngectomy market share
Slide 54: Atos improves lives following Total Laryngectomy
Atos improves the lives of patients following Total Laryngectomy procedures A Total Laryngectomy is a non-elective After surgery, a Voice Prosthesis (VP) is inserted by a healthcare professional, surgery performed in the advanced and the patient applies the Heat- and Moisture Exchanger (HME) and adh
Slide 55: Significant untapped potential in the laryngectomy market
There is significant untapped potential in the laryngectomy market today, which we will seek to eliminate The laryngectomy market, DKKbn Low level of market penetration due to: We will eliminate the ‘white space’ by: Lack of clinical standards in existing 01 markets outside of Northern Europe Settin
Slide 56: Tracheostomy patients have similar needs as Laryngectomy patients
Tracheostomy patients have similar needs as Laryngectomy patients, as they are both breathing through a neck stoma A Tracheostomy is a surgical The Tracheostomy patient journey starts with a cannula insertion, which can be procedure that creates an opening in reversed at any stage the neck for direc
Slide 57: Atos Medical financial assumptions
Atos Medical financial assumptions Organic growth and • Organic growth 8-10% EBITDA margin • EBITDA margin in the mid-30s level EPS impact • Increasingly EPS accretive from FY 2022/23 • Estimated run-rate operational synergies of up to DKK 100m from utilising Coloplast infrastructure with Synergies
Slide 58: Leading intimate healthcare – Appendices
Leading intimate healthcare Leading intimate healthcare Appendices Tabitha | IC user
Slide 59: The Coloplast share
The Coloplast share (COLO-B.CO) Holders of A shares and family 1 Danish institutions Foreign institutions Coloplast A/S Coloplast share listed on Nasdaq Copenhagen Other shareholders since 1983 Non-registered shareholders 4.0% 7.0% ~174.9 billion DKK (~26 billion USD) market cap @ ~823.4 DKK per sha
Slide 60: Capital structure
Capital structure Comments Net interest-bearing debt • Overall policy is that excess liquidity is returned to 2.7x shareholders through a combination of dividends and 2.3x share buy-backs 2.0x 21,263 • Bi-annual dividends 18,091 • Share buy-backs of DKK 500m per year 0.3x 1.0x expected – no buy-back
Slide 61: Solid organic growth of 8% in 9M 2022/23
Solid organic growth of 8% in 9M 2022/23 with continued good momentum across business areas and geographies 9M 2022/23 revenue by business area 9M 2022/23 revenue by geography Business Reported revenue Organic growth Share of organic Geographic Reported revenue Organic growth Share of organic area D
Slide 62: 9M reported growth was up 11%
9M reported growth was up 11%, with ~4%-points contribution from the Atos Medical acquisition and ~1%-point headwind from currencies 9M 2022/23 Revenue development (DKKm) 9M 2022/23 highlights • Organic growth was 8% or DKK 1,248 million, driven by: 1,754m DKK • Solid growth in Chronic Care across r
Slide 63: Reported EBIT margin of 28% in 9M
Reported EBIT margin of 28%1 in 9M, reflecting impact from cost inflation, increased level of commercial activity and amortisation costs 9M 2022/23 EBIT margin development before special items (%) 9M 2022/23 highlights • Gross margin was 67%, against 69% in 9M last year 30.8 -2.0 • Negative impact f
Slide 64: Key value ratios
Key value ratios Profitability drivers Free Cash Flow drivers 32.7 33.3 36.2 36.8 32.3 34.7 34.6 34.7 31.2 32.0 31.5 32.4 28.7 29.0 28.7 28.2 30.1 30.7 26.9 25.4 23.4 23.6 23.4 23.7 4.0 4.2 4.1 3.9 4.5 4.6 5.0 5.2 5.0 4.7 4.1 3.5 3.9 3.9 3.8 3.9 3.8 3.5 17/18 18/19 19/20 20/21 21/22 YTD 22/23 17/18
Slide 65: Coloplast revenue development by business area
Coloplast revenue development by business area Ostomy Care Interventional Urology Voice & Respiratory Care* 8 6 6 10 7 19 16 7 7 6 13 Contribution to reported growth 6%-points 4%-points 5 4 14 8,620 14 11 7,841 Organic growth (5 months) 9% 7,166 7,538 10 9 6,724 -7 2,424 1,970 1,835 -7 2,097 2,031 N
Slide 66: Revenue development by geography and total
Coloplast revenue development by geography and total Europe Other Developed Markets 6 4 15 9 2 5 6 2 4 5 16 21 12,916 16 10,573 10,820 11,261 10,404 8 6 10 11 6 3 5 4,785 5,775 4,757 4,380 4,644 18/19 19/20 20/21 21/22 YTD 22/23 18/19 19/20 20/21 21/22 YTD 22/23 FY 21/22 and YTD 22/23 reported growt
Slide 67: Segment operating profit
Segment operating profit (Excludes shared/non-allocated costs) Segment Operating Profit DKKm Segment Operating Profit Margin (%) Chronic Care Interventional Urology Wound & Skin Care Voice & Respiratory Care Ostomy and Continence Care 59 58 58 57 58 2,397 2,500 2,456 2,375 2,476 35 37 36 35 35 42 38
Slide 68: 9M 2022/23 Atos Medical impact on EBIT
9M 2022/23 Atos Medical impact on EBIT Atos Medical acquisition EBIT impact 32% 3% 29% 29% 28% 0% 28% 1% 0% DKK 5 million DKK 159 DKK 86 DKK 547 million million million (DKK 49m million related to Atos Medical integration costs) EBIT margin Special EBIT margin Atos EBIT 9M Amortisation EBITA Depreci
Slide 69: Exchange rate exposure and hedging policy
Exchange rate exposure FY 2022/23 and hedging policy Revenue FX exposure 2022/23(1) 12 months exposure from 10% initial exchange rate drop(1) Other 18% -490 USD -220 EUR 36% CNY, JPY, AUD, BRL & ARS -320 12% GBP -220 HUF 0 130 14% GBP 20% Revenue (DKKm) EBIT (DKKm) USD Foreign exchange rate guidance
Slide 70: US Mesh litigation – overview of financial impact
US Mesh litigation – Overview of financial impact P&L – overview of special items related to the Mesh Balance Cash flow litigation Assets Actual/Expected cash flow, DKKbn 13/14 - 18/19 19/20 20/21 21/22 YTD Restricted cash, DKKbn Actual cash flow Expected cash flow 17/18 22/23 0.5 0.5 EBIT (before s
Slide 71: Stable global health reforms environment
Stable global health reforms environment Europe Rest of World • Netherlands: Reimbursement pressure on OC and CC • U.S.: Reimbursement pressure on OC and CC (Managed Care) • France: Reimbursement pressure on WC • Italy: Regional payback system (retroactive) 71 Reimbursement pressure
Slide 72: CARE helps increase retention and product compliance
CARE helps us increase retention and improve product compliance We co-develop CARE content with CARE is a personal and “high- Global program with shared local clinicians touch” program infrastructure Advisors available on phone Clinically validated content and call protocol - ERP Website with reliab
Slide 73: DtC marketing program reaches into the community
With our DtC marketing program we reach into the community We operate in numerous channels to expose our …and with the reach we get several benefits service and product offering… Expose innovative products Ensure product accessibility Ensure successful experience 73
Slide 74: Generic model for distribution and reimbursement
The generic model for distribution and reimbursement of our products Prescription & Insurance Product Reimbursement price Prescription & Insurance Payer Distribution Consumer $ Product 74
Slide 75: Interventional Urology revenue is balanced
Interventional Urology’s revenue is balanced geographically and across the four business areas Interventional Urology at a Glance 15-20% market share in global market of DKK 13-14bn FY 21/22 market growing 3-5% annually 11% Coloplast position, FY 21/22 of Coloplast sales Endourology Men’s Health Wom
Slide 76: Interventional Urology is split into four business areas
Coloplast Interventional Urology is split into four business areas Men’s Women’s Bladder health Endourology & surgery Health Health • Erectile Dysfunction • Stress Urinary Incontinence • Stone Management • Bladder Drainage • Male Incontinence (SUI) • Transurethral • Benign prostatic hyperplasia • Te
Slide 77: Strong presence in Interventional Urology with room to capture share
We have a strong presence in our categories in Interventional Urology but there is room to capture market share 1 Men’s Health Women’s Health Endourology Bladder Health & 1 Surgery Inflatable Penile Male Stress urinary Pelvic organ Prosthesis (IPP) incontinence incontinence prolapse Fragmented Compe
Slide 78: Refined product roadmap in Interventional Urology
We are executing a refined product roadmap in Interventional Urology aligned to Strive25; progress is tracking to key milestones Strategy Description Men’s Health Women’s Health Endourology Projects that address regulatory Cadence of stone Strengthen core requirements, close gaps and maintain IPP En
Slide 79: Growth through product and therapy expansion
We will deliver growth through product and therapy expansion Tissue Fixation System Implantable Tibial Nerve TECHNOLOGY ASSESSMENT Stimulator Launched 22/23 Launching 25/26 ACTIVELY PURSUING POP SUI AUS Cancer ED IU Today OAB Endo Endo Consum- ables Laser Endo Visualization Soprano® BPH Hybrid Guide
Slide 80: Nine Continents acquisition to enter the OAB market
With the acquisition of Nine Continents, we are executing on the option to enter the attractive OAB market with Intibia Overactive bladder (OAB) market Why Implantable Tibial Nerve Stimulation (ITNS)? Less invasive ITNS complete in single procedure +80m people globally suffer from OAB symptoms proce
Slide 81: Global Advanced Wound Care market remains large and growing
The global Advanced Wound Care market* remains large and growing The Advanced Wound Care market* remains a significant Silicone Foams and Gelling Fibers are the two biggest value pool and is expected to grow despite the pandemic categories and grow faster than the market Market size in DKKbn Market
Slide 82: Wound & Skin Care 2025 strategic plan
The Wound & Skin Care 2025 strategic plan Scale our China business Build on positive momentum in EU by strengthening our commercial in silicone and 3DFit Technology and foundation and accelerate in silicone increase share of voice in selected with 3DFit Technology markets Scale our US business in Ac
Slide 83: In US Ostomy Care we continue to win
In US Ostomy Care we continue to win across patient pathway We have gained significant share over the last years … as we work on multiple fronts to win across the patient pathway 3-5 days >60 days ~10 years Bags & Plates acute share Acute Post-acute Community +10%-pts Patients’ first (incl. HHA) Lon
Slide 84: Access to Vizient and Premier GPOs
Coloplast has been awarded access to Vizient and Premier GPOs, ensuring a level playing field in ~75% of acute accounts Coloplast has been awarded access to Vizient and Premier, the two largest GPOs in the US Acute members1 Estimated Contract start date Contract Contract Acute share2 length type 3,6
Slide 85: Sustainability - key priorities and actions
Sustainability - key priorities and actions Improving products Reducing emissions Responsible and packaging operations Why is this a key priority: Why is this a key priority: Why is this a key priority: As a manufacturer of medical products made primarily As a growing company, we are challenged by a
Slide 86: 9M 22/23 progress on key sustainability ambitions
9M 22/23 progress on key sustainability ambitions Improving products and packaging Reducing emissions2 Responsible operations 2025 9M FY 2025 9M FY 2025 9M FY Ambition 22/23 21/22 Ambition 22/23 21/22 Ambition 22/23 21/22 100% 2.4 2.4 90% 2.0 Recyclable 78% Scope 1+2 emissions Lost time injury packa
Slide 87: Introducing Ostomy Care
Introducing Key products Ostomy Care Disease areas • Colorectal cancer (est. 45%) • Bladder cancer (est. 10%) SenSura® Mio Concave SenSura® Mio Convex SenSura® Mio • Diverticulitis (est. 15%) Launched in 2018-2019 Launched in 2015 Launched in 2014 • Inflammatory bowel disease (est. 10%) • Other (est
Slide 88: Supporting Products
Introducing Key products Ostomy Care Supporting Products Market fundamentals Brava® Protective Seal Brava® Skin Barrier Brava® Elastic Tape Designed for leakage and skin Reducing skin problems Elastic so it follows • Market size of DKK 3-4bn protection without affecting adhesion the body and • Marke
Slide 89: Introducing Continence Care
Introducing Key products Continence Care Disease areas • Spinal Cord Injured, SCI Luja™ SpeediCath® Flex Set SpeediCath® Navi SpeediCath® Flex • Spina Bifida, SB Intermittent catheter with Intermittent Set catheter Intermittent catheter Intermittent catheter • Multiple Sclerosis, MS Micro-hole Zone
Slide 90: Bowel Management
Introducing Key products Bowel Management Disease areas Faecal incontinence (management products only) Peristeen® Plus Anal Irrigation Peristeen® Anal Irrigation Launched in 2021 Launched in 2003 Customer groups Updated in 2011 • Spinal Cord Injured, SCI • Spina Bifida, SB • Multiple Sclerosis, MS M
Slide 91: Laryngectomy
Introducing Key products - Laryngectomy Voice & Respiratory Care Provox® Life ™ Laryngectomy Heat and Moisture Exchangers (HMEs) Home Go Night Protect Energy Free hands Disease areas • People that have undergone a total Provox® Life ™ laryngectomy, a typical treatment for Adhesive advanced laryngeal
Slide 92: Tracheostomy
Introducing Voice & Respiratory Care Tracheostomy Disease areas Key products - Tracheostomy • Performed when the airways are restricted, e.g., during an emergency when the airways are Portfolio expansion blocked, or when a disease or other problem • Strengthened the tracheostomy makes normal breathi
Slide 93: Surgical treatment of urological disorders
Introducing Key products Interventional Urology Surgical treatment of urological disorders Disease areas Titan® Touch Inflatable Penile Prosthesis Altis® single incision sling • Urinary incontinence Launched in 2013, Men’s health Launched in 2012 Women’s health – Surgical Urology • Pelvic organ prol
Slide 94: Wound Care
Key products Introducing Wound Care Disease areas Chronic wounds Biatain® Silicone Non-Border Biatain® Fiber Biatain® Contact • Leg ulcers Silicone foam dressing without a Reinforced gelling fiber. Silicone contact layer. • Diabetic foot ulcers border. Launched in 2021 Launched in 2020 Launched in 2
Slide 95: Skin Care
Introducing Key products Skin Care Disease areas • Moisture associated skin damage Sween® EasiCleanse® Bath • Incontinence Broad line of skin care products Disposable bathing wipes • Skin folds & obesity Designed to increase consistency of care Improves patient experience • Prevention of skin impair
Slide 96: US Skin Care
At a glance US Skin Care US Skin Care market Market Market drivers drivers andand limiters limiters + +AgingAging and obese population and obese population US market size estimated + +CMSCMSValueValue BasedBased Purchasing Purchasing at DKK 4-5bn with 2-4% growth + +Increased focusfocus Increased on
Slide 97: Coloplast organisation: Chronic Care and Strategic Business Units
The Coloplast organisation is divided into Chronic Care and Strategic Business Units, running on shared global business support functions Coloplast Group Chronic Care Strategic Business Unit Wound Interventional Voice & Ostomy Care Continence Care & Skin Care Urology Respiratory Care Marketing Marke
Slide 98: The Coloplast Executive Leadership Team
The Coloplast Executive Leadership Team Kristian Villumsen President, CEO (Born 1970) With Coloplast since 2008 Nicolai Buhl Andersen Anders Lonning-Skovgaard Paul Marcun Dorthe Rønnau Allan Rasmussen EVP, Innovation EVP, CFO EVP, Growth SVP, People & Culture EVP, Operations (Born 1969) (Born 1972)
Slide 99: Income statement
Income statement DKKm Q3 2021/22 Q3 2022/23 Change 9M 2021/22 9M 2022/23 Change Revenue 5,849 6,108 4% 16,520 18,274 11% Gross profit 4,048 4,023 -1% 11,359 12,196 7% SG&A costs -2,083 -2,128 2% -5,654 -6,449 14% R&D costs -222 -216 -3% -649 -641 -1% Other operating income/expenses 18 7 -61% 40 25 -
Slide 100: Balance sheet
Balance sheet DKKm 30 Jun 2022 30 Jun 2023 Change Balance, total 35,185 35,087 0% Assets Non-current assets 26,482 25,414 -4% Current assets 8,703 9,673 11% of which: Inventories 3,022 3,557 18% Trade receivables 3,837 4,072 6% Marketable securities, cash, and cash equivalents 854 855 0% 675 Equity
Slide 101: Cash flow
Cash flow DKKm 9M 2021/22 9M 2022/23 Change EBIT 4,661 5,126 10% Amortisation 174 245 41% Depreciation 497 547 10% Adjustment for other non-cash operating items 75 -166 nm Change in working capital -1,161 -1,314 13% Net interest payments -202 -582 188% Paid tax -1,085 -1,511 39% Cash flow from opera
Slide 102: Manufacturing setup
Manufacturing setup Production by country (Volume)¹ 3% 5% Hörby Hungary Mørdrup 0% Tatabánya China 11% Minneapolis Nieder-Olm 4% Nyirbátor Mankato Sarlat US/France Denmark Zhuhai Costa Rica Costa Rica Atos (SE/DE) 77% COGS by cost type² 11% 9% Salary - Direct 6% 12% Salary - Indirect Materials (RM &
Slide 103: Production sites
Production sites Hungary China Tatabánya Zhuhai • Ostomy care products • Continence care products • Adhesives • Ostomy care products • Continence care products • Machine building • Interventional Urology products • Number of employees in production: ~800 • Number of employees in production: ~1,650 T
Slide 104: Production sites
Production sites Denmark Germany Mørdrup Nieder-Olm • Pilot development work Ostomy care, • Specialised production Continence care and Wound care • Research & Development centre and • Adhesives production manufacturing of tracheostomy products • Number of employees in production: ~200 • Number of em
Slide 105: Global Operations Plan 6 themes
Our Global Operations Plan 6 will be announced in 2023, key themes will be resilience and optimizing the footprint Moving focus of GOP6 to further strengthening our model while delivering continued leverage effect on fixed costs and efficiency improvement 2008 2009 2012 2017 2020 2023-2026 Turn-arou
Slide 106: Coloplast Sponsored Level 1 ADR programme
Coloplast Sponsored Level 1 ADR programme Coloplast Sponsored ADR Programme Benefits of a Coloplast ADR programme to US Investors: • Coloplast has established a sponsored ADR programme in the US, as a Symbol CLPBY service to US investors by offering an alternative way to trade Coloplast shares, whil
Slide 107: Contact Investor Relations
Contact Investor Relations Holtedam 1 DK-3050 Humlebæk Denmark Aleksandra Dimovska Kristine Husted Munk Senior Director, Investor Relations Senior Manager, Investor Relations Tel. direct: +45 4911 2458 Tel. direct: +45 4911 3266 Office: +45 4911 1800 Office: +45 4911 1800 dkadim@coloplast.com dkkhu@
Slide 108: Mission, values and vision
Mission Making life easier for people with intimate healthcare needs Values Closeness… to better understand Passion… to make a difference Respect and responsibility… to guide us Vision Setting the global standard for listening and responding